Page last updated: 2024-12-06

ferric citrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ferric citrate is an iron(III) salt of citric acid. It is a coordination complex that is soluble in water. It is used as a dietary supplement to treat iron deficiency anemia. It is also used as a food additive and as a reagent in chemical reactions. Ferric citrate is synthesized by reacting citric acid with iron(III) hydroxide. It is a yellow-brown solid that is soluble in water. Ferric citrate is a reducing agent and can be used to reduce other metal ions. It is also a chelating agent and can bind to metal ions, forming complexes. Ferric citrate is a potential treatment for iron deficiency anemia. It is also being studied for its potential to treat other conditions, such as Alzheimer's disease and cancer. Ferric citrate is a safe and effective treatment for iron deficiency anemia. It is generally well-tolerated, although some people may experience side effects, such as stomach upset or constipation. Ferric citrate is a valuable compound with a wide range of applications. It is a safe and effective treatment for iron deficiency anemia and is being studied for its potential to treat other conditions.'

ferric citrate: RN given refers to Fe(+3)[1:1] salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

iron(III) citrate : An iron chelate resulting from the combination of iron(3+) and citrate(3-). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID61300
CHEBI ID144421
SCHEMBL ID42945
MeSH IDM0084509

Synonyms (74)

Synonym
iron citrate, fec6h5o7
nsc-112227
iron(iii) citrate
3522-50-7
citric acid, iron(3+) salt (1:1)
ferric citrate
2338-05-8
ferric citrate tetrahydrate
1,2,3-propanetricarboxylic acid, 2-hydroxy-, iron salt
iron 2-hydroxy-1,2,3-propanetricarboxylate
iron(iii)-citrate
iron citrate
citric acid, iron salt
ccris 6843
ferric citrate anhydrous
1,2,3-propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt (1:1)
zerenex
jtt-751
iron(3+) citrate
2-hydroxypropane-1,2,3-tricarboxylate; iron(3+)
FT-0652224
CHEBI:144421 ,
krx-0502
fe(3+)-citrate
iron(3+) 2-hydroxypropane-1,2,3-tricarboxylate
auryxia
iron(3+); 2-oxidanylpropane-1,2,3-tricarboxylate
A832727
6043-74-9
1,2,3-propanetricarboxylic acid, 2-hydroxy-, iron salt (1:?)
ferric citrate [usan]
iron (iii) citrate
jtt 751
1,2,3-propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt
einecs 249-117-0
citric acid, iron(3+) salt
28633-45-6
AKOS015918266
einecs 222-536-6
63g354m39z ,
nsc 112227
ferric citrate (van)
fexeric
iron, (hydrogen citrato(3-))-
unii-63g354m39z
FT-0626407
FT-0627304
ferric citrate [who-dd]
ferric citrate [mi]
iron(iii) citrate tribasic
ferrum citricum [hpus]
ferrum citricum
ferric citrate [fcc]
ferric citrate [inci]
ferric citrate [orange book]
2-hydroxy-1,2,3-propanetricarboxylic acid iron salt
SCHEMBL42945
NPFOYSMITVOQOS-UHFFFAOYSA-K
ferriccitrate
DTXSID0037657 ,
DB09162
iron(iii)citrate
Q15628111
iron(iii) citrate;iron citrate
BCP30645
2-hydroxypropane-1,2,3-tricarboxylate;iron(3+)
iron(iii) citrate; zerenex
iron(iii) 2-hydroxypropane-1,2,3-tricarboxylate
citric acid,iron(3+)salt
CS-0030977
HY-N1428C
(2-hydroxypropane-1,2,3-tricarboxylato(3-)-kappa(3)o(1),o(2),o(3))iron
dtxcid8017657
2338-05-8 (hydrate), 3522-50-7 (anhydrous)

Research Excerpts

Overview

Ferric citrate hydrate (FC) is an oral iron-based phosphate binder that is used to treat hyperphosphatemia in patients with chronic kidney disease (CKD) It is also used as a phosphate (Pi) binder for dialysis-dependent CKD and for iron deficiency anemia (IDA) in non-dialysis CKD.

ExcerptReferenceRelevance
"Ferric citrate is an effective phosphate binder with favorable safety profile in ESRD patients. "( Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial.
Chiu, YW; Lee, CC; Lee, CT; Leu, JG; Peng, YS; Tarng, DC; Wu, MJ; Wu, MS, 2022
)
2.45
"Ferric citrate hydrate (FC) is an oral iron-based phosphate binder that is used to treat hyperphosphatemia in patients with chronic kidney disease (CKD). "( Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study.
Hashimoto, T; Ito, K; Matsumoto, Y; Nishino, N; Okuda, Y; Susai, H; Yamada, R; Yokoyama, K, 2022
)
2.46
"Ferric citrate (FC) is an approved therapy for chronic kidney disease (CKD) patients as a phosphate (Pi) binder for dialysis-dependent CKD, and for iron deficiency anemia (IDA) in non-dialysis CKD. "( Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.
Agoro, R; Allen, MR; Clinkenbeard, EL; Damrath, JG; Hum, JM; Liesen, MP; Ni, P; Noonan, ML; Swallow, EA; Wallace, JM; White, KE, 2022
)
2.46
"Ferric citrate is an oral phosphate binder that decreases dietary phosphate absorption and serum FGF23 concentrations while increasing iron stores and hemoglobin in patients with CKD."( Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
Capella, M; Courbon, G; David, V; Dussold, C; Francis, C; Gerber, C; Isakova, T; Martin, A; Mehta, R; Neuburg, S; Qi, L; Wang, X; Wolf, M, 2019
)
2.68
"Ferric citrate is a phosphate binder that may also be used to treat iron-deficiency anemia. "( Ferric citrate: cardio- and renoprotective in chronic kidney disease?
Hanudel, MR, 2019
)
3.4
"Ferric citrate is an oral iron-based phosphate binder, being known to affect iron status and improve iron deficiency anemia (IDA) in chronic kidney disease (CKD) patients. "( Conventional and novel impacts of ferric citrate on iron deficiency anemia and phosphorus metabolism in rats.
Iida, A; Matsushita, M; Ohta, T; Yamada, T, 2020
)
2.28
"Ferric citrate (FC) is an iron-containing phosphate binder used as a food additive for iron supplementation. "( Iron Overload Resulting from the Chronic Oral Administration of Ferric Citrate Impairs Intestinal Immune and Barrier in Mice.
Chen, Z; Huang, C; Lao, C; Liu, W; Luo, Q; Ma, W; Xia, Y, 2021
)
2.3
"Ferric citrate is an approved phosphate binder for use in patients with chronic kidney disease on dialysis. "( Ferric citrate controls serum phosphorus in dialysis patients: retrospective data
.
Chillemi, S; Gerbeling, T; Hain, DJ; Huffman, JM; Koeper, DW; Loram, LC; Marinaro, M; Pergola, PE; Pritsiolas, JM; Rosenthal, MA, 2017
)
3.34
"Ferric citrate complex is a dietary phosphate binder prescribed for patients with end-stage kidney disease to treat hyperphosphatemia and secondary hyperparathyroidism."( The Phosphate Binder Ferric Citrate Alters the Gut Microbiome in Rats with Chronic Kidney Disease.
Comeau, AM; England, W; Khazaeli, M; Langille, MGI; Lau, WL; Nunes, ACF; Phan, J; Suematsu, Y; Vaziri, ND; Whiteson, K, 2018
)
1.52
"Ferric citrate is a dietary phosphate binder used to control hyperphosphatemia in CKD patients."( Ferric Citrate Attenuates Cardiac Hypertrophy and Fibrosis in a Rat Model of Chronic Kidney Disease.
Goto, M; Jing, W; Khazaeli, M; Lau, WL; Nunes, ACF; Suematsu, Y; Vaziri, ND, 2019
)
2.68
"Ferric citrate hydrate (FC) is an iron-based phosphate binder approved for hyperphosphataemia in patients with chronic kidney disease. "( Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study.
Akiba, T; Fukagawa, M; Hanaki, K; Hirakata, H; Ito, K; Nakayama, M; Wolf, M; Yokoyama, K, 2019
)
2.25
"Ferric citrate appears to be an effective way to decrease ruminal H2S concentrations, which could allow producers to safely increase the inclusion of ethanol co-products."( Ferric citrate decreases ruminal hydrogen sulphide concentrations in feedlot cattle fed diets high in sulphate.
Doane, P; Drewnoski, ME; Hansen, SL, 2014
)
2.57
"Ferric citrate hydrate is a novel iron-based phosphate binder being developed for hyperphosphatemia in patients with CKD."( Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
Akiba, T; Block, GA; Fukagawa, M; Hirakata, H; Kumagai, Y; Nakayama, M; Sawada, K; Yokoyama, K, 2014
)
3.29
"Ferric citrate (FC) is a new phosphorus binder shown to increase serum iron stores while reducing intravenous iron and erythropoiesis-stimulating agent usage. "( Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs.
Dwyer, JP; Jackson, JH; Lewis, JB; Niecestro, R; Rodby, R; Sika, M; Umanath, K, 2015
)
2.17
"Ferric citrate (FC) is a phosphate binder with shown efficacy and additional effects on iron stores and use of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs). "( Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.
Blumenthal, SS; Dwyer, JP; Greco, BA; Greene, T; Hiremath, AN; Jalal, DI; Koury, MJ; Lewis, JB; Ma, KN; Manley, J; Negoi, DG; Niecestro, R; Reisin, E; Sika, M; Umanath, K; Umeukeje, EM; Zeig, S, 2015
)
3.3
"Ferric citrate is an iron-based oral phosphate binder that effectively lowers serum phosphorus levels."( The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Abraham, JD; Arfeen, SS; Bowline, IG; Chernin, G; Dwyer, JP; Fadem, SZ; Goral, S; Greene, T; Koury, M; Lewis, JB; Middleton, J; Sika, M; Sinsakul, MV; Umanath, K; Van Buren, PN; Weiner, DE, 2015
)
1.46
"Ferric citrate is an effective phosphate binder with a safety profile comparable to sevelamer and calcium acetate."( The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Abraham, JD; Arfeen, SS; Bowline, IG; Chernin, G; Dwyer, JP; Fadem, SZ; Goral, S; Greene, T; Koury, M; Lewis, JB; Middleton, J; Sika, M; Sinsakul, MV; Umanath, K; Van Buren, PN; Weiner, DE, 2015
)
1.46
"Ferric citrate (FC) is a novel, iron-based phosphate binder that increases iron stores and decreases i.v."( Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data.
Bond, TC; Dwyer, JP; Lewis, J; Niecestro, R; Rodby, RA; Sika, M; Umanath, K, 2015
)
2.58
"Ferric citrate (FC) is an iron-containing phosphate binder that has been shown to effectively decrease serum phosphate, increase hemoglobin, and replete iron stores in patients with chronic kidney disease. "( Ferric Citrate in Patients With Chronic Kidney Disease.
Block, GA, 2016
)
3.32

Effects

Ferric citrate (FC) has been used as an iron fortifier and nutritional supplement. It is reported to induce colitis in rats, however the underlying mechanism remains to be elucidated.

ExcerptReferenceRelevance
"Ferric citrate (FC) has been used as an iron fortifier and nutritional supplement, which is reported to induce colitis in rats, however the underlying mechanism remains to be elucidated. "( Ferric citrate-induced colonic mucosal damage associated with oxidative stress, inflammation responses, apoptosis, and the changes of gut microbial composition.
Chen, Z; Fang, J; Geng, Y; Guo, H; He, J; Huang, C; Jahangir, A; Liu, W; Luo, Q; Ouyang, P; Pan, T; Shi, L; Shi, R; Tang, L; Wei, X; Xia, Y, 2023
)
3.8
"Ferric citrate has been used as a food additive for supplementation of iron. "( A 13-week subchronic toxicity study of ferric citrate in F344 rats.
Akagi, J; Cho, YM; Mizuta, Y; Ogawa, K; Toyoda, T, 2014
)
2.11
"Ferric citrate (FC) has demonstrated efficacy as a phosphate binder and reduces the requirements for erythropoiesis-stimulating agents (ESAs) and intravenous (IV) iron in dialysis patients. "( Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model.
Brunelli, SM; Chertow, GM; Hsieh, A; Sharma, A; Sibbel, SP; Van Wyck, D, 2017
)
2.2
"Ferric citrate has been tested in phase 2 trials as a phosphate binder."( Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
Anger, M; Blumenthal, SS; Chang, IJ; Dwyer, JP; Kaplan, M; Koury, MJ; Lewis, JB; Schulman, G; Sika, M; Smith, M; Zeig, S, 2013
)
1.4

Treatment

Ferric citrate treatment increased mean TSAT from 22% ± 7% (SD) to 32% ± 14% and reduced serum phosphate levels from 4.5 ± 0.6 to 3.9±0.6 mg/dL. placebo exerted no effect on TSAT (21% ± 8% to 20%   ± 8%) and less effect on serum phosphate level. Co-treatment with ferriccitrate quenched the effect of deferoxamine, confirming the role of iron in PAI-1 regulation.

ExcerptReferenceRelevance
"Ferric citrate treatment increased mean TSAT from 22% ± 7% (SD) to 32% ± 14% and reduced serum phosphate levels from 4.5 ± 0.6 to 3.9 ± 0.6 mg/dL, while placebo exerted no effect on TSAT (21% ± 8% to 20% ± 8%) and less effect on serum phosphate level (4.7 ± 0.6 to 4.4 ± 0.8 mg/dL; between-group P<0.001 for each). "( A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
Block, GA; Chertow, GM; Fishbane, S; Pergola, PE; Rodriguez, M; Shemesh, S; Smits, G; Wolf, M, 2015
)
2.11
"Ferric citrate treatment did not affect the serum concentration of aluminium."( An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate.
Hou, CC; Hsu, CH; Wu, TH; Yang, CS; Yang, WC; Young, EW, 2002
)
1.26
"Treatment with ferric citrate significantly increased hemoglobin and serum iron concentrations, reduced serum phosphate and NT-proBNP levels and ameliorated hypertension, heart/body weight ratio, cardiac hypertrophy, fibrosis and inflammation."( Ferric Citrate Attenuates Cardiac Hypertrophy and Fibrosis in a Rat Model of Chronic Kidney Disease.
Goto, M; Jing, W; Khazaeli, M; Lau, WL; Nunes, ACF; Suematsu, Y; Vaziri, ND, 2019
)
2.3
"Treatment with ferric citrate attenuated renal failure and cardiovascular abnormalities including myocardial hypertrophy and fibrosis in CKD rats."( Ferric Citrate Attenuates Cardiac Hypertrophy and Fibrosis in a Rat Model of Chronic Kidney Disease.
Goto, M; Jing, W; Khazaeli, M; Lau, WL; Nunes, ACF; Suematsu, Y; Vaziri, ND, 2019
)
2.31
"Co-treatment with ferric citrate quenched the effect of deferoxamine, confirming the role of iron in PAI-1 regulation."( Iron-mediated stability of PAI-1 mRNA in adenocarcinoma cells-involvement of a mRNA-binding nuclear protein.
Harish Kumar, M; Maruyama, M; Omura, S; Radha, KS; Sugiki, M; Yoshida, E, 2005
)
0.65

Toxicity

ExcerptReferenceRelevance
" Ammonium tetrathiomolybdate was itself toxic after injection into the hippocampus, but this toxicity was reduced by formation of a metal ion/tetrathiomolybdate complex with Cu+2."( Comparative effects of metal chelating agents on the neuronal cytotoxicity induced by copper (Cu+2), iron (Fe+3) and zinc in the hippocampus.
Armstrong, C; Lees, GJ; Leong, W, 2001
)
0.31
" Four serious adverse events were reported; none were related to the study drug."( The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients.
Dwyer, J; Greene, T; Korbet, S; Koury, M; Lewis, J; Shapiro, W; Sika, M; Sinsakul, M; Smith, M, 2012
)
0.66
"Ferric citrate was well tolerated by patients after 4 weeks with no significant clinical or biochemical adverse events related to exposure."( The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients.
Dwyer, J; Greene, T; Korbet, S; Koury, M; Lewis, J; Shapiro, W; Sika, M; Sinsakul, M; Smith, M, 2012
)
2.11
"Safety endpoints were adverse events and adverse drug reactions."( Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
Akiba, T; Chertow, GM; Fukagawa, M; Hirakata, H; Kumagai, Y; Nakayama, M; Sawada, K; Yokoyama, K, 2014
)
0.4
" The most common adverse events were gastrointestinal disorders, which were mild to moderate in intensity."( Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis.
Akiba, T; Chertow, GM; Fukagawa, M; Hirakata, H; Kumagai, Y; Nakayama, M; Sawada, K; Yokoyama, K, 2014
)
0.4
" Although proper use of these compounds is necessary for the prevention of iron deficiency, their indiscriminate use could potentially cause insidious adverse consequences."( Safety Issues in Iron Treatment in CKD.
Vaziri, ND, 2016
)
0.43
" Multivariable time-dependent Cox regression jointly related the primary safety outcome (composite of cardiac, infection, gastrointestinal, and hepatobiliary serious adverse events) to moving averages of ferritin and transferrin saturation over the preceding 90 days with covariate adjustment."( The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis
.
Dwyer, JP; Greco, B; Greene, T; Hunsicker, LG; Jalal, DI; Koury, MJ; Lewis, JB; McFadden, M; Niecestro, R; Sika, M; Umanath, K, 2017
)
0.66
" Treatment-emergent adverse events (AEs) were reported in 143 of 190 (75."( Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease.
Block, GA; Chertow, GM; Fishbane, S; Neylan, JF; Pergola, PE; Uhlig, K, 2017
)
0.77
" No severe adverse drug reactions were observed in either the patients receiving FCH or SFOH."( Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
Fujino, T; Kaburagi, N; Morimoto, K; Oya, M; Takemitsu, TY; Yamashita, N; Yoshida, T, 2022
)
0.96
"The results of the present study suggest that the iron-based phosphate binders, FCH and SFOH, decrease serum phosphate concentrations consistently and are safe to use over the long-term in maintenance hemodialysis patients."( Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
Fujino, T; Kaburagi, N; Morimoto, K; Oya, M; Takemitsu, TY; Yamashita, N; Yoshida, T, 2022
)
0.96
" The most common treatment-emergent adverse events were gastrointestinal-related with discolored feces (41."( Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial.
Chiu, YW; Lee, CC; Lee, CT; Leu, JG; Peng, YS; Tarng, DC; Wu, MJ; Wu, MS, 2022
)
1
" Adverse drug reactions, iron- and erythrocyte-related parameters (i."( Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study.
Hashimoto, T; Ito, K; Matsumoto, Y; Nishino, N; Okuda, Y; Susai, H; Yamada, R; Yokoyama, K, 2022
)
1.02

Bioavailability

ExcerptReferenceRelevance
" In subjects with depleted iron stores the relative bioavailability was decreased from 100 to 14% for the HP-Fe."( Intestinal absorption of 59Fe from neutron-activated commercial oral iron(III)-citrate and iron(III)-hydroxide-polymaltose complexes in man.
Heinrich, HC, 1987
)
0.27
" Citrate alone is poorly absorbed by symbiosomes; this uptake is greatly enhanced by addition of iron."( Uptake of iron by symbiosomes and bacteroids from soybean nodules.
Meyer, JM; Moreau, S; Puppo, A, 1995
)
0.29
" The bioavailability of iron was examined by measuring hemoglobin concentration, hematocrit value, and tissue iron stores."( Recovery from iron deficiency in rats by the intake of recombinant yeast producing human H-ferritin.
Chang, YJ; Hwang, EH; Jo, MY; Kim, KS; Park, CU, 2005
)
0.33
" The aim of the present study was to determine the bioavailability of Fe in cocoa using the Hb regeneration efficiency (HRE) method."( Iron bioavailability of cocoa powder as determined by the Hb regeneration efficiency method.
Konomi, A; Otagi, M; Yokoi, K, 2009
)
0.35
"The slope-ratio assay is being used as a gold standard for determining iron bioavailability in foods."( Comparison of a modified hemoglobin regeneration efficiency method with a slope-ratio assay in measuring relative bioavailability of cocoa powder iron using rats.
Konomi, A; Otagi, M; Yokoi, K, 2011
)
0.37
") lines with contrasting Fe bioavailability (ie."( High bioavailability iron maize (Zea mays L.) developed through molecular breeding provides more absorbable iron in vitro (Caco-2 model) and in vivo (Gallus gallus).
Glahn, RP; Hoekenga, OA; Kochian, LV; Tako, E, 2013
)
0.39
" Hemoglobin maintenance efficiency (HME) and total body Hb Fe values were used to estimate Fe bioavailability from the diets."( High bioavailability iron maize (Zea mays L.) developed through molecular breeding provides more absorbable iron in vitro (Caco-2 model) and in vivo (Gallus gallus).
Glahn, RP; Hoekenga, OA; Kochian, LV; Tako, E, 2013
)
0.39
"Natural polyamines such as putrescine (Put), spermidine (Spd), and spermine (Spm), which are present in the human diet in large amounts, associated with their active transporter, are assumed to play a role in non-heme iron uptake and iron bioavailability from nutrients."( Involvement of polyamines in iron(III) transport in human intestinal Caco-2 cell lines.
Brissot, P; Cannie, I; Gaboriau, F; Gouffier, L; Lepage, S; Lescoat, G; Loréal, O; Lowe, O; Morel, I; Ropert, M, 2013
)
0.39
" In contrast, bioavailability of iron for epithelial cells was moderately decreased under these conditions."( Iron-induced virulence of Salmonella enterica serovar typhimurium at the intestinal epithelial interface can be suppressed by carvacrol.
Burt, SA; de Jonge, MI; Kortman, GA; Roelofs, RW; Swinkels, DW; Tjalsma, H, 2014
)
0.4
" This was completed by the operational determination of the iron bioavailability using an in-vitro simulated model for gastro-intestinal digestion."( Mass spectrometry-based analytical developments to link iron speciation to iron bioavailability in maize.
Hoekenga, O; Lobinski, R; Ouerdane, L; Szpunar, J; Wang, S, 2019
)
0.51
" Elevating dietary micronutrient iron (Fe) intake can reduce Pb oral bioavailability while being beneficial for child nutritional health."( Effects of various Fe compounds on the bioavailability of Pb contained in orally ingested soils in mice: Mechanistic insights and health implications.
Juhasz, AL; Li, HB; Li, SW; Lin, XY; Ma, LQ; Wang, HY; Xue, RY; Zhang, S; Zhang, YS; Zhou, DM; Zhou, L, 2022
)
0.72

Dosage Studied

Primary outcome is dose-response of ferric citrate on serum phosphorus level. Secondary outcomes are safety and tolerability. We related safety profiles, erythropoiesis-stimulating agent (ESA), and intravenous iron dosing to achieved iron stores in 441 subjects.

ExcerptRelevanceReference
" This study investigated the dose-response and safety of JTT-751 among Japanese hemodialysis patients."( Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial.
Akiba, T; Hirakata, H; Kumagai, Y; Sawada, K; Yokoyama, K, 2012
)
0.69
"5-grams, 3-grams and 6-grams/day groups, respectively, demonstrating a dose-response relationship up to 6 g/day."( Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial.
Akiba, T; Hirakata, H; Kumagai, Y; Sawada, K; Yokoyama, K, 2012
)
0.69
" This trial was designed as a dose-response and efficacy trial."( Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
Anger, M; Blumenthal, SS; Chang, IJ; Dwyer, JP; Kaplan, M; Koury, MJ; Lewis, JB; Schulman, G; Sika, M; Smith, M; Zeig, S, 2013
)
0.68
"Primary outcome is dose-response of ferric citrate on serum phosphorus level; secondary outcomes are safety and tolerability."( Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
Anger, M; Blumenthal, SS; Chang, IJ; Dwyer, JP; Kaplan, M; Koury, MJ; Lewis, JB; Schulman, G; Sika, M; Smith, M; Zeig, S, 2013
)
0.95
" Over the past decade, the prescription and dosage of both iron therapies and erythropoiesis-stimulating agents have shifted, with notable regional differences observed."( Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients.
Locatelli, F; Mazzaferro, S; Yee, J, 2016
)
0.43
" Using multicenter trial data, we related safety profiles, erythropoiesis-stimulating agent (ESA), and intravenous iron dosing to achieved iron stores in 441 subjects randomized 2 : 1 to ferric citrate or active control as their phosphate binder over 52 weeks."( The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis
.
Dwyer, JP; Greco, B; Greene, T; Hunsicker, LG; Jalal, DI; Koury, MJ; Lewis, JB; McFadden, M; Niecestro, R; Sika, M; Umanath, K, 2017
)
0.85
" Low dosage significantly improved mycelium growth, without affecting hyphal morphology."( Bacteria-produced ferric exopolysaccharide nanoparticles as iron delivery system for truffles (Tuber borchii).
Amicucci, A; Arshakyan, M; Baldi, F; Burattini, S; Chiarantini, L; Ciccimarra, G; Falcieri, E; Gallo, M; Iotti, M; Leonardi, P; Picceri, GG; Piccoli, G; Vallorani, L; Zambonelli, A, 2018
)
0.48
"In the FCH group, Hb, transferrin saturation, ferritin, HEP-25 and ERFE levels were all significantly increased, while inorganic phosphorus levels, dosage of erythropoietin-stimulating agent, and erythropoietin resistance index were all significantly decreased after drug administration."( Hepcidin-25/erythroferrone ratio predicts improvement of anaemia in haemodialysis patients treated with ferric citrate hydrate.
Asao, R; Goto, Y; Gotoh, H; Hara, M; Inagaki, M; Kenmotsu, S; Kiuchi, Y; Nakamura, M; Nakamura, Y; Nishida, K; Ohsawa, I; Suzuki, H; Tsuji, M, 2019
)
0.73
" This study investigated long-term efficacy and safety of different FC dosing regimens for treating anemia in nondialysis-dependent CKD (NDD-CKD)."( Ferric Citrate Dosing in Iron Deficiency Anemia in Nondialysis-Dependent Chronic Kidney Disease.
Belo, D; Crawford, P; Farag, YMK; Goldfarb-Rumyantzev, A; Luo, W; Moustafa, M; Pergola, PE, 2021
)
2.06
" At week 12, dosage was increased to 2 tablets TID (6 g/day) or 3 tablets BID (6 g/day) in patients whose hemoglobin (Hb) levels increased <0."( Ferric Citrate Dosing in Iron Deficiency Anemia in Nondialysis-Dependent Chronic Kidney Disease.
Belo, D; Crawford, P; Farag, YMK; Goldfarb-Rumyantzev, A; Luo, W; Moustafa, M; Pergola, PE, 2021
)
2.06
"FC administered BID and TID for 48 weeks was safe and effective for treating anemia in this population, supporting potentially increased dosing flexibility."( Ferric Citrate Dosing in Iron Deficiency Anemia in Nondialysis-Dependent Chronic Kidney Disease.
Belo, D; Crawford, P; Farag, YMK; Goldfarb-Rumyantzev, A; Luo, W; Moustafa, M; Pergola, PE, 2021
)
2.06
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (1 Product(s))

Product Categories

Product CategoryProducts
Pet Supplies1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Vital Planet Vital Dog™ Daily Multivitamin Beef -- 30 Chewable TabletsVital PlanetPet Suppliesascorbic acid, kelp, d-calcium pantothenate, dicalcium phosphate, Vitamin D3, Choline, Vitamin E, methylsulfonylmethane, iron citrate, Folic Acid, Vitamin E, Iodine, Manganese, Niacin, Pantothenic Acid, potassium chloride, potassium iodide, Pyridoxine, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamine, Vitamin B122024-11-29 10:47:42

Roles (2)

RoleDescription
anti-anaemic agentA compound which increases either the number of red cells or the amount of haemoglobin in the blood.
nutraceuticalA product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
iron chelate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (426)

TimeframeStudies, This Drug (%)All Drugs %
pre-199054 (12.68)18.7374
1990's78 (18.31)18.2507
2000's104 (24.41)29.6817
2010's144 (33.80)24.3611
2020's46 (10.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.33 (24.57)
Research Supply Index6.16 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index134.14 (26.88)
Search Engine Supply Index2.64 (0.95)

This Compound (60.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials30 (6.77%)5.53%
Reviews25 (5.64%)6.00%
Case Studies2 (0.45%)4.05%
Observational5 (1.13%)0.25%
Other381 (86.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]